Will Cragg @willjcragg.bsky.social · 10/02/2025Regarding MHRA performance, she mentions that MHRA has been doing well vs statutory timelines for review. New regulations will include measures to make approvals quicker 100
Will Cragg @willjcragg.bsky.social · 10/02/2025Regarding automatic approvals: new regs ensure only appropriate trials will be able to follow this route. Criteria designed in consultation with suitable experts in trials. She confirms that any safety concerns with medicinal products will make the trial ineligible for the notification scheme 100
Will Cragg @willjcragg.bsky.social · 10/02/2025Re stakeholder consultation and avoiding unintended consequences - she gives the example of the consultation resulting in patient and public involvement being excluded from the regulations, but supported by suitable guidance instead 100
